IHAM
Integral Health Asset Management Portfolio holdings
AUM
$1.07B
This Quarter Return
-9.51%
1 Year Return
+40.53%
3 Year Return
+328.04%
5 Year Return
+535.34%
10 Year Return
–
AUM
$486M
AUM Growth
+$486M
(+27%)
Cap. Flow
+$142M
Cap. Flow
% of AUM
29.12%
Top 10 Holdings %
Top 10 Hldgs %
40.72%
Holding
86
New
15
Increased
40
Reduced
9
Closed
21
Top Buys
| 1 |
Eli Lilly
LLY
|
$23.7M |
| 2 |
Sanofi
SNY
|
$17.5M |
| 3 |
Centene
CNC
|
$16.9M |
| 4 |
McKesson
MCK
|
$13.6M |
| 5 |
DexCom
DXCM
|
$12.4M |
Top Sells
| 1 |
Pfizer
PFE
|
$15.5M |
| 2 |
Globus Medical
GMED
|
$13.3M |
| 3 |
Acadia Healthcare
ACHC
|
$9.83M |
| 4 |
AMED
Amedisys
AMED
|
$6.89M |
| 5 |
Cigna
CI
|
$5.99M |
Sector Composition
| 1 | Healthcare | 97.07% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Elevance Health
ELV
$71.8B
| $32.7M | 6.73% | 67,840 +22,840 | +51% | +$11M |
|
|
2
Centene
CNC
$14.3B
| $29.6M | 6.09% | 350,000 +200,000 | +133% | +$16.9M |
|
|
3
Eli Lilly
LLY
$657B
| $23.7M | 4.87% | +73,059 | New | +$23.7M |
|
4
Cytokinetics
CYTK
$4.23B
| $20.6M | 4.24% | 525,000 +55,000 | +12% | +$2.16M |
|
|
5
Sanofi
SNY
$121B
| $17.5M | 3.6% | +350,000 | New | +$17.5M |
|
6
Guardant Health
GH
$8.41B
| $15.5M | 3.2% | 385,291 +285,291 | +285% | +$11.5M |
|
7
AstraZeneca
AZN
$248B
| $15.5M | 3.19% | 234,830 +134,830 | +135% | +$8.91M |
|
8
Envista
NVST
$3.52B
| $14.9M | 3.06% | 386,165 +136,165 | +54% | +$5.25M |
|
|
CCXI
9
DELISTED
ChemoCentryx, Inc.
CCXI
| $14.2M | 2.93% | 574,029 +174,029 | +44% | +$4.31M |
|
|
10
McKesson
MCK
$85.4B
| $13.6M | 2.8% | +41,748 | New | +$13.6M |
|
|
SAGE
11
DELISTED
Sage Therapeutics
SAGE
| $13.3M | 2.74% | 412,257 +101,257 | +33% | +$3.27M |
|
12
Tenet Healthcare
THC
$16.3B
| $13.2M | 2.71% | 250,485 +120,485 | +93% | +$6.33M |
|
13
CVS Health
CVS
$92.8B
| $13.1M | 2.69% | 140,898 +50,898 | +57% | +$4.72M |
|
|
14
DexCom
DXCM
$29.5B
| $12.4M | 2.56% | +166,991 | New | +$12.4M |
|
15
BioMarin Pharmaceuticals
BMRN
$11.2B
| $10.5M | 2.15% | 126,286 +46,286 | +58% | +$3.84M |
|
16
Revvity
RVTY
$10.5B
| $9.65M | 1.98% | 67,840 -7,160 | -10% | -$1.02M |
|
17
Zentalis Pharmaceuticals
ZNTL
$122M
| $9.56M | 1.97% | 340,243 +125,243 | +58% | +$3.52M |
|
18
Merck
MRK
$210B
| $9.52M | 1.96% | 104,369 +29,369 | +39% | +$2.68M |
|
|
SWAV
19
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
| $8.98M | 1.85% | 46,966 +16,966 | +57% | +$3.24M |
|
20
Kura Oncology
KURA
$686M
| $8.46M | 1.74% | 461,310 +124,310 | +37% | +$2.28M |
|
21
Alkermes
ALKS
$4.78B
| $7.8M | 1.61% | 261,966 +11,966 | +5% | +$356K |
|
22
Amicus Therapeutics
FOLD
$2.34B
| $7.57M | 1.56% | 704,490 +480,490 | +215% | +$5.16M |
|
23
Perrigo
PRGO
$3.27B
| $7.41M | 1.52% | +182,645 | New | +$7.41M |
|
24
Relay Therapeutics
RLAY
$619M
| $7.31M | 1.5% | 436,262 +109,262 | +33% | +$1.83M |
|
25
Alnylam Pharmaceuticals
ALNY
$58.5B
| $6.85M | 1.41% | +46,966 | New | +$6.85M |
|